Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1998 April; 77(8): 1355–1362.
PMCID: PMC2150148

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.


This study evaluates the degree and relevance of persisting ototoxicity after cisplatin-based standard-dose chemotherapy for testicular cancer, with emphasis on identification of potential factors for an increased risk of this late sequel. Hearing thresholds of 86 patients with a median age of 31 years (range 21-53 years) and a median follow-up time of 58 months (range 15-159 months) were assessed by conventional pure-tone audiometry. Interviews were conducted evaluating the patients' history with special regard to audiological risk factors, as well as circumstances of ototoxic symptoms. Details concerning treatment and patient variables were extracted retrospectively from the patients' charts. An additional screening programme assessed current body functions, blood parameters and other late toxicities. Symptomatic ototoxicity persisted in 20% of patients (59% tinnitus, 18% hearing loss, 23% both), while 10% had experienced completely reversible ototoxic symptoms for a duration of 1-18 months after treatment. Symptoms were bilateral in 81% of patients. Hearing thresholds were compatible with cisplatin-induced hearing loss in 42% of audiograms performed. Subjective (history) and objective (audiogram) findings were not always consistent. The following statistically significant risk factors for ototoxicity were established: high cumulative dose of cisplatin (P < 0.0001); history of noise exposure (P = 0.006). Additionally, high doses of vincristine (P = 0.001) seemed to result in reversible ototoxic symptoms. No other independent risk factors were identified. In conclusion, persisting ototoxicity represents a clinical sequel for approximately 20% of testicular cancer patients treated at standard dose but may affect more than 50% of patients receiving cumulative doses of cisplatin > 400 mg m(-2). Previous noise exposure may also result in a threefold increased risk for cisplatin ototoxicity. Future studies should use these risk factors as important stratification criteria for trials aiming at the evaluation and prevention of cisplatin-induced ototoxicity.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aass N, Kaasa S, Lund E, Kaalhus O, Heier MS, Fosså SD. Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer. 1990 Jan;61(1):151–155. [PMC free article] [PubMed]
  • Aguilar-Markulis NV, Beckley S, Priore R, Mettlin C. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol. 1981;16(2):111–123. [PubMed]
  • Bissett D, Kunkeler L, Zwanenburg L, Paul J, Gray C, Swan IR, Kerr DJ, Kaye SB. Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer. 1990 Oct;62(4):655–659. [PMC free article] [PubMed]
  • Black FO, Myers EN, Schramm VL, Johnson J, Sigler B, Thearle PB, Burns DS. Cisplatin vestibular ototoxicity: preliminary report. Laryngoscope. 1982 Dec;92(12):1363–1368. [PubMed]
  • Blakley BW, Gupta AK, Myers SF, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg. 1994 May;120(5):541–546. [PubMed]
  • Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996 Nov;14(11):2923–2932. [PubMed]
  • Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997 Jul 24;337(4):242–253. [PubMed]
  • Boyer M, Raghavan D, Harris PJ, Lietch J, Bleasel A, Walsh JC, Anderson S, Tsang CS. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol. 1990 Jan;8(1):21–26. [PubMed]
  • Brock P, Bellman S. Ototoxicity of cisplatinum. Br J Cancer. 1991 Jan;63(1):159–160. [PMC free article] [PubMed]
  • Church MW, Kaltenbach JA, Blakley BW, Burgio DL. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res. 1995 Jun;86(1-2):195–203. [PubMed]
  • Dolev E, Tamir A, Leventon G. "Is magnesium depletion the reason for ototoxicity caused by aminoglycosides?". Med Hypotheses. 1983 Apr;10(4):353–358. [PubMed]
  • Doménech J, Carulla M, Traserra J. Los acúfenos en el diagnóstico y pronóstico de la ototoxicidad. Acta Otorrinolaringol Esp. 1990 Jan-Feb;41(1):7–9. [PubMed]
  • Dreschler WA, vd Hulst RJ, Tange RA, Urbanus NA. The role of high-frequency audiometry in early detection of ototoxicity. Audiology. 1985;24(6):387–395. [PubMed]
  • Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear. 1994 Jun;15(3):232–239. [PubMed]
  • Fosså SD, Aass N, Kaalhus O, Klepp O, Tveter K. Long-term survival and morbidity in patients with metastatic malignant germ cell tumors treated with cisplatin-based combination chemotherapy. Cancer. 1986 Dec 15;58(12):2600–2605. [PubMed]
  • Gratton MA, Salvi RJ, Kamen BA, Saunders SS. Interaction of cisplatin and noise on the peripheral auditory system. Hear Res. 1990 Dec;50(1-2):211–223. [PubMed]
  • Günther T, Rebentisch E, Vormann J, König M, Ising H. Enhanced ototoxicity of gentamicin and salicylate caused by Mg deficiency and Zn deficiency. Biol Trace Elem Res. 1988 Jun;16(1):43–50. [PubMed]
  • Hallmark RJ, Snyder JM, Jusenius K, Tamimi HK. Factors influencing ototoxicity in ovarian cancer patients treated with Cis-platinum based chemotherapy. Eur J Gynaecol Oncol. 1992;13(1):35–44. [PubMed]
  • Hansen SW. Late-effects after treatment for germ-cell cancer with cisplatin, vinblastine, and bleomycin. Dan Med Bull. 1992 Oct;39(5):391–399. [PubMed]
  • Hartwig S, Pettersson U, Stahle J. cis-Diamminedichloroplatinum: a cytostatic with an ototoxic effect. ORL J Otorhinolaryngol Relat Spec. 1983;45(5):257–261. [PubMed]
  • Helson L, Okonkwo E, Anton L, Cvitkovic E. cis-Platinum ototoxicity. Clin Toxicol. 1978;13(4):469–478. [PubMed]
  • Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996 Jul;14(7):2101–2112. [PubMed]
  • Laurell GF. Combined effects of noise and cisplatin: short- and long-term follow-up. Ann Otol Rhinol Laryngol. 1992 Dec;101(12):969–976. [PubMed]
  • Lautermann J, Song B, McLaren J, Schacht J. Diet is a risk factor in cisplatin ototoxicity. Hear Res. 1995 Aug;88(1-2):47–53. [PubMed]
  • Marco-Algarra J, Basterra J, Marco J. Cis-diaminedichloro platinum ototoxicity. An experimental study. Acta Otolaryngol. 1985 Mar-Apr;99(3-4):343–347. [PubMed]
  • McAlpine D, Johnstone BM. The ototoxic mechanism of cisplatin. Hear Res. 1990 Aug 15;47(3):191–203. [PubMed]
  • Melamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients. A preliminary report. Cancer. 1985 Jan 1;55(1):41–43. [PubMed]
  • Moul JW, Robertson JE, George SL, Paulson DF, Walther PJ. Complications of therapy for testicular cancer. J Urol. 1989 Dec;142(6):1491–1496. [PubMed]
  • Nakai Y, Konishi K, Chang KC, Ohashi K, Morisaki N, Minowa Y, Morimoto A. Ototoxicity of the anticancer drug cisplatin. An experimental study. Acta Otolaryngol. 1982 Mar-Apr;93(3-4):227–232. [PubMed]
  • Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol. 1992 Apr;10(4):574–579. [PubMed]
  • Piel IJ, Meyer D, Perlia CP, Wolfe VI. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep. 1974 Nov-Dec;58(6):871–875. [PubMed]
  • Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol. 1995 Jun;76(6):386–394. [PubMed]
  • Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep. 1982 Jan;66(1):19–23. [PubMed]
  • Riggs LC, Brummett RE, Guitjens SK, Matz GJ. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope. 1996 Apr;106(4):401–406. [PubMed]
  • Rybak LP, Ravi R, Somani SM. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol. 1995 Jul;26(2):293–300. [PubMed]
  • Saito T, Aran JM. Comparative ototoxicity of cisplatin during acute and chronic treatment. ORL J Otorhinolaryngol Relat Spec. 1994 Nov-Dec;56(6):315–320. [PubMed]
  • Schaefer SD, Post JD, Close LG, Wright CG. Ototoxicity of low- and moderate-dose cisplatin. Cancer. 1985 Oct 15;56(8):1934–1939. [PubMed]
  • Schilsky RL. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol. 1982 Mar;9(1):75–83. [PubMed]
  • Schwabe HR, Herrmann R, Mathew M, Gräf KJ, Sander T, Cordes M, Nagel R, Weissbach L, Huhn D. Langfristige Toxizität der Polychemotherapie bei kurativ behandeltem Hodenkarzinom. Dtsch Med Wochenschr. 1992 Jan 24;117(4):121–126. [PubMed]
  • Schweitzer VG. Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am. 1993 Oct;26(5):759–789. [PubMed]
  • Skinner R, Pearson AD, Amineddine HA, Mathias DB, Craft AW. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990 Jun;61(6):927–931. [PMC free article] [PubMed]
  • Stoter G, Koopman A, Vendrik CP, Struyvenberg A, Sleyfer DT, Willemse PH, Schraffordt Koops H, van Oosterom AT, ten Bokkel Huinink WW, Pinedo HM. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol. 1989 Aug;7(8):1099–1104. [PubMed]
  • Stuart NS, Woodroffe CM, Grundy R, Cullen MH. Long-term toxicity of chemotherapy for testicular cancer--the cost of cure. Br J Cancer. 1990 Mar;61(3):479–484. [PMC free article] [PubMed]
  • van der Hulst RJ, Dreschler WA, Urbanus NA. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol. 1988 Mar-Apr;97(2 Pt 1):133–137. [PubMed]
  • Vermorken JB, Kapteijn TS, Hart AA, Pinedo HM. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol. 1983 Jan;19(1):53–58. [PubMed]
  • Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear. 1991 Apr;12(2):91–102. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK